HFE and Non-HFE Hereditary Hemochromatosis Based on Screening of 854 Individuals: 12 Years of an Iranian Experience.

IF 1.1 4区 生物学 Q4 GENETICS & HEREDITY
Genetic testing and molecular biomarkers Pub Date : 2024-07-01 Epub Date: 2024-07-09 DOI:10.1089/gtmb.2023.0764
Razieh Zarifian Yeganeh, Masoumeh Akbari Kelishomi, Atiyeh Ahmadpour Jenaghard, Banafsheh Salmani, Zohreh Vahidi, Mina Makvand, Maryam Azad, Mahdieh Kooshki, Yassin Bouraqi, Azita Azarkeivan, Hossein Najmabadi, Maryam Neishabury
{"title":"<i>HFE</i> and Non-<i>HFE</i> Hereditary Hemochromatosis Based on Screening of 854 Individuals: 12 Years of an Iranian Experience.","authors":"Razieh Zarifian Yeganeh, Masoumeh Akbari Kelishomi, Atiyeh Ahmadpour Jenaghard, Banafsheh Salmani, Zohreh Vahidi, Mina Makvand, Maryam Azad, Mahdieh Kooshki, Yassin Bouraqi, Azita Azarkeivan, Hossein Najmabadi, Maryam Neishabury","doi":"10.1089/gtmb.2023.0764","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Introduction:</i></b> The genetics of hereditary hemochromatosis (HH) is understudied in Iran. Here, we report the result of genetic screening of 854 individuals, referred as \"suspected cases of HH,\" to a diagnostic laboratory in Iran over a 12-year period. <b><i>Materials and Methods:</i></b> From 2011 to 2012, 121 cases were screened for HH using Sanger sequencing of <i>HFE</i> exons. After 2012, this method was replaced by a commercial reverse hybridization assay (RHA) targeting 18 variants in the <i>HFE</i>, <i>TFR2</i>, and <i>FPN1(SLC40A1)</i> genes and 733 cases were screened using this method. <b><i>Results:</i></b> From the total studied population, HH was confirmed by genetic diagnosis in only seven cases (0.82%): two homozygotes for <i>HFE</i>:C282Y and five homozygotes for <i>TFR2</i>:AVAQ 594-597 deletion. In 254 cases (29.7%), H63D, C282Y, S65C, and four other <i>HFE</i> variants not targeted by RHA were identified. Although the resulting genotypes in the latter cases did not confirm HH, some of them were known modifying factors of iron overload or could cause HH in combination with a possibly undetected variant. No variant was detected in 593 cases (69.4%). <b><i>Conclusion:</i></b> This study showed that the spectrum of genetic variants of HH in the Iranian population includes <i>HFE</i> and <i>TFR2</i> variants. However, HH was not confirmed in the majority (99.2%) of suspected cases. This could be explained by limitations of our genetic diagnostics and possible inaccuracies in clinical suspicion of HH. A cooperative clinical and genetic investigation is proposed as a solution to this issue.</p>","PeriodicalId":12603,"journal":{"name":"Genetic testing and molecular biomarkers","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genetic testing and molecular biomarkers","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1089/gtmb.2023.0764","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/9 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The genetics of hereditary hemochromatosis (HH) is understudied in Iran. Here, we report the result of genetic screening of 854 individuals, referred as "suspected cases of HH," to a diagnostic laboratory in Iran over a 12-year period. Materials and Methods: From 2011 to 2012, 121 cases were screened for HH using Sanger sequencing of HFE exons. After 2012, this method was replaced by a commercial reverse hybridization assay (RHA) targeting 18 variants in the HFE, TFR2, and FPN1(SLC40A1) genes and 733 cases were screened using this method. Results: From the total studied population, HH was confirmed by genetic diagnosis in only seven cases (0.82%): two homozygotes for HFE:C282Y and five homozygotes for TFR2:AVAQ 594-597 deletion. In 254 cases (29.7%), H63D, C282Y, S65C, and four other HFE variants not targeted by RHA were identified. Although the resulting genotypes in the latter cases did not confirm HH, some of them were known modifying factors of iron overload or could cause HH in combination with a possibly undetected variant. No variant was detected in 593 cases (69.4%). Conclusion: This study showed that the spectrum of genetic variants of HH in the Iranian population includes HFE and TFR2 variants. However, HH was not confirmed in the majority (99.2%) of suspected cases. This could be explained by limitations of our genetic diagnostics and possible inaccuracies in clinical suspicion of HH. A cooperative clinical and genetic investigation is proposed as a solution to this issue.

基于 854 人筛查的 HFE 和非 HFE 遗传性血色沉着病:伊朗 12 年的经验
导言:伊朗对遗传性血色病(HH)的遗传学研究不足。在此,我们报告了伊朗一家诊断实验室在 12 年内对 854 例 "疑似 HH 病例 "进行基因筛查的结果。材料和方法:2011 年至 2012 年,使用 HFE 外显子的 Sanger 测序筛选了 121 例 HH 患者。2012 年后,该方法被针对 HFE、TFR2 和 FPN1(SLC40A1)基因中 18 个变体的商业反向杂交检测(RHA)所取代,并使用该方法筛查了 733 个病例。结果显示在所有研究人群中,仅有 7 例(0.82%)通过基因诊断确诊为 HH:2 例为 HFE:C282Y 的同卵双生型,5 例为 TFR2:AVAQ 594-597 缺失的同卵双生型。在 254 个病例(29.7%)中,发现了 H63D、C282Y、S65C 和其他 4 个不是 RHA 针对的 HFE 变异。虽然后者的基因型不能证实是 HH,但其中一些是已知的铁超载改变因素,或与可能未检测到的变异体结合可能导致 HH。在 593 个病例(69.4%)中未检测到变异体。结论这项研究表明,伊朗人群中的 HH 基因变异包括 HFE 和 TFR2 变异。然而,大多数疑似病例(99.2%)并未确诊为 HH。这可能是由于我们的基因诊断存在局限性,以及临床上对 HH 的怀疑可能不准确。建议通过临床和基因合作调查来解决这一问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.50
自引率
7.10%
发文量
63
审稿时长
1 months
期刊介绍: Genetic Testing and Molecular Biomarkers is the leading peer-reviewed journal covering all aspects of human genetic testing including molecular biomarkers. The Journal provides a forum for the development of new technology; the application of testing to decision making in an increasingly varied set of clinical situations; ethical, legal, social, and economic aspects of genetic testing; and issues concerning effective genetic counseling. This is the definitive resource for researchers, clinicians, and scientists who develop, perform, and interpret genetic tests and their results. Genetic Testing and Molecular Biomarkers coverage includes: -Diagnosis across the life span- Risk assessment- Carrier detection in individuals, couples, and populations- Novel methods and new instrumentation for genetic testing- Results of molecular, biochemical, and cytogenetic testing- Genetic counseling
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信